Founder of Ventyx Biosciences Picks Up 30% More Stock
Founder of Ventyx Biosciences Picks Up 30% More Stock
Those following along with Ventyx Biosciences, Inc. (NASDAQ:VTYX) will no doubt be intrigued by the recent purchase of shares by Raju Mohan, Founder of the company, who spent a stonking US$960k on stock at an average price of US$1.92. Aside from being a solid chunk in its own right, the deft move also saw their holding increase by some 30%.
跟随Ventyx Biosciences, Inc.(纳斯达克:VTYX)的人一定会对公司创始人Raju Mohan最近购买股份的消息感兴趣,他以平均价格US$1.92购入了价值高达96万美元的股票。 虽然这笔交易本身就相当可观,但这一巧妙的举动也使他们的持股增加了约30%。
Ventyx Biosciences Insider Transactions Over The Last Year
Ventyx Biosciences过去一年内部交易
In fact, the recent purchase by Raju Mohan was the biggest purchase of Ventyx Biosciences shares made by an insider individual in the last twelve months, according to our records. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$2.65. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.
事实上,根据我们的记录,Raju Mohan最近的购买是过去十二个月内Ventyx Biosciences股份中由内部人士进行的最大购买。尽管我们喜欢看到内部人士买入,但我们注意到这笔大额购买价格明显低于最近的US$2.65。由于这些股票以较低的价格购入,这次买入并不能告诉我们内部人士对当前股价的看法。
The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!
以下图表显示了过去一年中公司和个人的内部交易。单击下面的图表,即可查看每个内部交易的详细信息!
Ventyx Biosciences is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.
Ventyx Biosciences并不是唯一被内部人士买入的股票。所以请查看这个关于内部买入的低调公司的免费列表。
Does Ventyx Biosciences Boast High Insider Ownership?
Ventyx Biosciences是否拥有高比例的内部持股?
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Our data indicates that Ventyx Biosciences insiders own about US$7.1m worth of shares (which is 4.0% of the company). We do generally prefer see higher levels of insider ownership.
查看公司内部人士的总持股可以帮助你判断他们是否与普通股东的利益一致。通常,内部持股越高,内部人士越可能被激励来长期发展公司。我们的数据表明,Ventyx Biosciences的内部人士大约拥有价值710万美元的股票(约占公司4.0%)。我们一般更倾向于看到更高的内部持股水平。
So What Does This Data Suggest About Ventyx Biosciences Insiders?
那么这些数据对Ventyx Biosciences的内部人士有什么启示?
The recent insider purchase is heartening. And the longer term insider transactions also give us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. On this analysis the only slight negative we see is the fairly low (overall) insider ownership; their transactions suggest that they are quite positive on Ventyx Biosciences stock. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. To help with this, we've discovered 4 warning signs (1 is concerning!) that you ought to be aware of before buying any shares in Ventyx Biosciences.
最近的内部购入令人振奋。长期的内部交易也让我们感到信心。但另一方面,该公司去年亏损,这让我们有些谨慎。在这个分析中,我们看到的唯一稍微负面的因素是内部持股整体较低;他们的交易表明他们对Ventyx Biosciences的股票持相当积极的态度。因此,了解内部人士在买卖方面的动向非常有帮助,同时也有助于了解特定公司面临的风险。为此,我们发现了4个警示信号(其中一个令人担忧!),在购买Ventyx Biosciences的任何股份之前,您应该了解这些信号。
Of course Ventyx Biosciences may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
当然,Ventyx Biosciences可能并不是最好的买入股票。因此,您可能希望查看这个高质量公司的免费集合。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
对于本文而言,内部人是指向相关监管机构报告其交易的个人。我们目前仅考虑公开市场交易和直接利益的私人处置,但不包括衍生交易或间接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧吗?请直接与我们联系。或者,发送电子邮件至editorial-team @ simplywallst.com。
Simply Wall St的这篇文章是一般性质的。我们仅基于历史数据和分析师预测提供评论,使用公正的方法,我们的文章并非意在提供财务建议。这并不构成买入或卖出任何股票的建议,并且不考虑您的目标或财务状况。我们旨在为您带来基于基础数据驱动的长期聚焦分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St对提及的任何股票都没有持仓。